Navigation Links
N30 Pharma Announces Financing, Expansion of Board
Date:10/28/2008

BOULDER, Colo., Oct. 28 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that regulate nitric oxide bioavailability, announced today that it has completed a financing and expanded its Board of Directors.

N30 will use proceeds from this financing to advance its clinical program in Cystic Fibrosis and expand its discovery and preclinical research in the area of small molecule drugs that modulate nitric oxide bioavailability in cardiopulmonary diseases. The financing is the company's second since its formation in 2007. Joining the company's Board of Directors are Arnold Snider and Marc Elia. Mr. Snider will assume the role of Chairman of the Board.

Mr. Snider previously founded and managed Deerfield Management, a New York-based multi-billion dollar hedge fund focused on healthcare and life-sciences companies. Mr. Snider is also on the Board of Directors of the Christopher and Dana Reeve Foundation and is a trustee of Davidson College.

Mr. Elia co-founded N30 while at Tiger Management, a New York hedge fund, and has had previous roles in life sciences corporate strategy at Chiron Corporation and L.E.K. Consulting.

"I am pleased with our investors' ongoing commitment to the major clinical potential of N30 Pharma, particularly in difficult economic times. In addition, I welcome Arnie and Marc to their roles on the Board. Arnie is widely regarded as one of the premier healthcare investors in the world. Marc brings a multitude of talents and intellect to the N30 Board. I look forward to drawing on their expertise and long experience with biopharmaceutical companies as we continue to move N30 forward," commented Charles Scoggin, M.D., President and CEO of N30.

About N30 Pharma

N30 Pharma is a clinical-stage company developing s-nitrosothiol therapies for major unmet needs in cardiopulmonary diseases. S-nitrosothiols are endogenous molecules that
'/>"/>

SOURCE N30 Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
2. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
3. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
4. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
5. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
6. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
7. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
8. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
9. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
10. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
11. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Chilcott,Limited (Nasdaq: WCRX ) announced today that it ... the market opening on Friday,November 9, 2007. The ... audio webcast,on Friday, November 9, 2007 at 8:00 AM ... call, please dial (888) 503-8171 in the,United States and ...
... The Cervical Spine Now Available In ... ... Trinity,Clinic Neurosurgeon and Director of the Trinity Mother Frances Neuroscience,Institute is the ... that can provide some patients a chance to maintain,motion in their necks ...
... System delivers unmatched out-of-the-box functionality, BENSALEM, ... (Stelex), the market leader in providing enterprise-wide,compliance ... the,Quality Management System (QMS) module for Livelink ... provider of Enterprise Content,Management (ECM) software and ...
Cached Biology Technology:Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck 2Stelex Announce QMS Module for Open Text's Livelink ECM 2Stelex Announce QMS Module for Open Text's Livelink ECM 3
(Date:11/18/2014)... --  News Highlights: , ... Partners Data Lake, an agile data and analytics ... allow researcher and clinicians to explore and develop ... of patients , The Partners Data Lake ... Partners system, breaking down physical barriers for collaboration ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/12/2014)... GARDENS, Fla. , Nov. 12, 2014 ... announced today that its U.are.U ® fingerprint readers ... bakery chain in Central Mexico . ... June 2014 to eliminate payroll issues caused by employees ... to installing the U.are.U fingerprint readers, Montparnasse relied on ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... ocean where an essential nutrientironis scarce, a marine bacterium that ... biochemical trick: It recycles iron. By day, it uses ... night, it appears to reuse the same iron in different ... Crocosphaera watsonii , is one of the few marine ...
... Rochelle, NY, January 10, 2011The mega-mergers of 2009 did not ... each had a price tag of more than $40 billion, ... to an evaluation of reported deals conducted by Genetic Engineering ... mega takeover for the year, sanofi-aventis, move to buy Genzyme, ...
... CHAMPAIGN, Ill. Using detailed land analysis, Illinois ... land could produce up to half of the world,s ... pastureland. Published in the journal Environmental Science ... environmental engineering professor Ximing Cai identified land around the ...
Cached Biology News:'Hot-bunking' bacterium recycles iron to boost ocean metabolism 2'Hot-bunking' bacterium recycles iron to boost ocean metabolism 3GEN reports on biotech acquisition deals in 2010 that topped $1 billion 2Study estimates land available for biofuel crops 2
... Gene Pulser Xcell eukaryotic system, ... Hz, is used for electroporation ... includes the main unit, CE ... range) or square-wave pulses, ShockPod ...
Request Info...
... 96 and PowerPac basic power supply are used ... in agarose gels. This Model 96 cell includes ... UV-transparent gel tray with fluorescent ruler, and a ... and 220-240 V, provides output of 10-300 V, ...
... This CE-based system provides clear advantages ... (viral load, gene expression), mutation analysis, ... easy-to-use system with microplate connectivity is ... and quality control. The P/ACE ...
Biology Products: